Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DPJ Lawmakers Call for Withdrawal of Proposal to Unify Basic Dispensing Fees
July 11, 2011
- DPJ's Diet Members Adopt Opinion Paper Calling for Deregulating Online Sales of OTC Drugs
July 11, 2011
- Mediceo to Use Its MR-Certified MSs to Promote Orphan Drugs
July 11, 2011
- Ono, Evotec Succeed in Discovering Lead Compounds in Iron Channel Drug Discovery
July 11, 2011
- Eisai to Enhance Liver Disease Franchise in Asia/Pacific Region
July 11, 2011
- Pfizer Remains Top Global Drug Maker; Mergers Shake up Ranking
July 11, 2011
- Sanofi-aventis, Tohoku Univ. Sign Comprehensive Agreement for Life Science Research
July 11, 2011
- 24 APIs/34 Products Approved Following New Procedures
July 11, 2011
- Kyowa Hakko Kirin Starts Domestic PIII Trial for KW-3357
July 11, 2011
- Approvals for 3 Dasen-Like Drugs to Be Withdrawn
July 11, 2011
- AnGes MG Obtains Substance Patent for Novel Peptide AG-30 in Japan
July 11, 2011
- METI's Council Proposes Review of Patients' Drug Copayments
July 11, 2011
- Sawai May Embark on Follow-on Antibody Drugs in Mid-2010s: President Sawai
July 11, 2011
- Application for Partial Changes Acceptable When Crystal Form Is Changed: Korosho
July 11, 2011
- Towa to Actively Develop Value Added Generics
July 11, 2011
- Korosho to Study Application of Cost-Benefit Assessment to Reimbursement Pricing
July 11, 2011
- Research-oriented Companies Provide Reliable Info. on Generics: Prof. Kobayashi
July 11, 2011
- PMDA to Bring Domestic GMP into Greater Harmony with PIC/S GMP
July 11, 2011
- Hospitals Lose Money by Using Herceptin for Stomach Cancer: Chuikyo's DPC Subcommittee
July 11, 2011
- Sanofi-aventis K.K. Aiming for Growth in “Upper Single Digits” Pres. Moulding
July 11, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…